{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T09:10:13Z","timestamp":1759050613045,"version":"3.44.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jneuroim.2021.577803","type":"journal-article","created":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T11:18:57Z","timestamp":1640863137000},"page":"577803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Serum HGF and APN2 are associated with disability worsening in SPMS"],"prefix":"10.1016","volume":"364","author":[{"given":"Isabelle","family":"Tottenham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Camara-Lemarroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2021.577803_bb0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00401-004-0954-8","article-title":"Mitochondrial damage and histotoxic hypoxia: a pathway of tissue injury in inflammatory brain disease?","volume":"109","author":"Aboul-Enein","year":"2005","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.jneuroim.2021.577803_bb0010","series-title":"Hepatocyte Growth Factor Mediates Mesenchymal Stem Cell\u2013Induced Recovery in Multiple Sclerosis Models","first-page":"862","volume":"vol. 15","author":"Bai","year":"2012"},{"key":"10.1016\/j.jneuroim.2021.577803_bb0015","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.4049\/jimmunol.1302338","article-title":"Hepatocyte growth factor limits autoimmune neuroinflammation via glucocorticoid-induced leucine zipper expression in dendritic cells","volume":"193","author":"Benkhoucha","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2021.577803_bb0020","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1365-2990.2010.01139.x","article-title":"Review: cerebral microvascular pathology in ageing and neurodegeneration","volume":"37","author":"Brown","year":"2011","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.jneuroim.2021.577803_bb0025","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/BF00296505","article-title":"Evidence of persistent blood-brain barrier abnormalities in chronic progressive multiple sclerosis","volume":"90","author":"Claudio","year":"1995","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.jneuroim.2021.577803_bb0030","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/ana.24006","article-title":"Neurological deficits caused by tissue hypoxia in neuroinflammatory disease","volume":"74","author":"Davies","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577803_bb0035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.clim.2017.05.019","article-title":"Multimarker risk stratification approach at multiple sclerosis onset","volume":"181","author":"Fern\u00e1ndez-Paredes","year":"2017","journal-title":"Clin. Immunol."},{"issue":"2","key":"10.1016\/j.jneuroim.2021.577803_bb0040","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s40478-014-0084-z","article-title":"Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis","volume":"22","author":"Girolamo","year":"2014","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.jneuroim.2021.577803_bb0045","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1750-3639.2003.tb00485.x","article-title":"Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult","volume":"13","author":"Graumann","year":"2006","journal-title":"Brain Pathol."},{"key":"10.1016\/j.jneuroim.2021.577803_bb0050","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/brain\/awaa427","article-title":"Hypoxia in multiple sclerosis; is it the chicken or the egg?","volume":"144","author":"Halder","year":"2021","journal-title":"Brain."},{"key":"10.1016\/j.jneuroim.2021.577803_bb0055","doi-asserted-by":"crossref","first-page":"12952","DOI":"10.1073\/pnas.1912839117","article-title":"Inflammation-related plasma and CSF biomarkers for multiple sclerosis","volume":"117","author":"Huang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jneuroim.2021.577803_bb0060","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1212\/WNL.0000000000010346","article-title":"Serum neurofilament light as a biomarker in progressive multiple sclerosis","volume":"95","author":"Kapoor","year":"2020","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2021.577803_bb0065","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jneuroim.2016.11.005","article-title":"Angiogenic factors are associated with multiple sclerosis","volume":"301","author":"Karampoor","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577803_bb0070","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1172\/JCI124012","article-title":"Enhanced glycolytic metabolism supports transmigration of brain-infiltrating macrophages in multiple sclerosis","volume":"129","author":"Kaushik","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2021.577803_bb0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4062\/biomolther.2019.119","article-title":"The role of a neurovascular signaling pathway involving hypoxia-inducible factor and notch in the function of the central nervous system","volume":"28","author":"Kim","year":"2020","journal-title":"Biomol. Ther. (Seoul)"},{"key":"10.1016\/j.jneuroim.2021.577803_bb0080","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/path.1434","article-title":"Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination","volume":"201","author":"Kirk","year":"2003","journal-title":"J. Pathol."},{"key":"10.1016\/j.jneuroim.2021.577803_bb0085","doi-asserted-by":"crossref","first-page":"e2313","DOI":"10.1212\/WNL.0000000000011863","article-title":"Repurposing Domperidone in secondary progressive multiple sclerosis: a Simon 2-stage phase 2 futility trial","volume":"96","author":"Koch","year":"2021","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2021.577803_bb0090","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1172\/JCI130308","article-title":"Angiopoietin-2 blockade ameliorates autoimmune neuroinflammation by inhibiting leukocyte recruitment into the CNS","volume":"130","author":"Li","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2021.577803_bb0095","doi-asserted-by":"crossref","first-page":"22680","DOI":"10.1074\/jbc.M109.006551","article-title":"Angiopoietin 2 mediates the differentiation and migration of neural progenitor cells in the subventricular zone after stroke","volume":"284","author":"Liu","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jneuroim.2021.577803_bb0100","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1097\/NEN.0b013e31823a8b6a","article-title":"Angiogenesis is regulated by angiopoietins during experimental autoimmune encephalomyelitis and is indirectly related to vascular permeability","volume":"70","author":"Macmillan","year":"2011","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577803_bb0105","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.autrev.2014.11.013","article-title":"Hepatocyte growth factor: a regulator of inflammation and autoimmunity","volume":"14","author":"Molnarfi","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jneuroim.2021.577803_bb0110","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jneuroim.2012.06.008","article-title":"Cerebrospinal hepatocyte growth factor levels correlate negatively with disease activity in multiple sclerosis","volume":"251","author":"M\u00fcller","year":"2012","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577803_bb0115","article-title":"Hypoxia-inducible factor-1: regulatory mechanisms and drug development in stroke","volume":"105742","author":"Pan","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jneuroim.2021.577803_bb0120","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jnen\/61.10.914","article-title":"Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats","volume":"61","author":"Proescholdt","year":"2002","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577803_bb0125","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/cam4.460","article-title":"Clinical implications of hypoxia biomarker expression in head and neck squamous cell carcinoma: a systematic review","volume":"4","author":"Swartz","year":"2015","journal-title":"Cancer Med."},{"key":"10.1016\/j.jneuroim.2021.577803_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128952","article-title":"Plasma biomarkers discriminate clinical forms of multiple sclerosis","volume":"10","author":"Tejera-Alhambra","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2021.577803_bb0135","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S1474-4422(09)70043-2","article-title":"Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis","volume":"8","author":"Trapp","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2021.577803_bb0140","doi-asserted-by":"crossref","first-page":"16477","DOI":"10.1038\/srep16477","article-title":"Reduced cortical microvascular oxygenation in multiple sclerosis: a blinded, case-controlled study using a novel quantitative near-infrared spectroscopy method","volume":"5","author":"Yang","year":"2015","journal-title":"Sci. Rep."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572821003301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572821003301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:41:05Z","timestamp":1759048865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572821003301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":28,"alternative-id":["S0165572821003301"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577803","relation":{},"ISSN":["0165-5728"],"issn-type":[{"type":"print","value":"0165-5728"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum HGF and APN2 are associated with disability worsening in SPMS","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577803","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"577803"}}